Drug firms in India say village card vaccine development progress

Press time: 2016-02-05

Source: xinhua The China youth network

Xinhua news agency in new Delhi on February 5 (xinhua Wu Jiang) a pharmaceutical company in India has claimed that the company village card important progress was made in vaccine research and development work, will be entered into the phase of animal experiments in the near future.

The company called "biotechnology in India", is located in south-central India hyderabad, specializing in the production of vaccines and biological drugs. Krishna, head of the company, she has told the media that the experts are two different types of village card vaccine, belongs to the inactivated vaccine and gene recombinant vaccine respectively. This the sample of the two vaccines have been developed and entered the stage of animal experiments in about two weeks.

According to introducing, the company began to research and development of village card vaccine a year ago, and tropical diseases related to dengue vaccine at the same time. Village with dengue virus belong to yellow card virus, is transmitted by aedes mosquitoes. Indian summer hot and rainy, mosquito-borne infectious diseases such as dengue fever outbreak.

Indian council of medical research director Sue mia swami natanz told local media said that at present of the two kinds of "potential vaccine candidates too early to comment," council of medical research has formed a team of experts, to evaluate its effectiveness to carry out.

According to the world health organization (who), village card virus itself is not life threatening, but the virus can cause small head disease and other diseases of the nervous system should cause the attention of the public health departments. Village card virus is currently in rapid spread of America, America has more than 20 countries and regions report found that the virus infection.

Medicine there is currently no vaccine for the village card virus and effective treatment. Countries such as America, Britain, France and Brazil government and pharmaceutical companies have recently announced that will boost village card vaccine development.